Drug interactions with tacrolimus

Drug Safety

Volumn 25, Issue 10, 2002, Pages 707-712

  Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLARITHROMYCIN; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN; DANAZOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUCONAZOLE; GANCICLOVIR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GRAFT REJECTION; GRAPEFRUIT JUICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE CELL; INTESTINE VILLUS; PRIORITY JOURNAL; REVIEW; TOXICITY; TRANSPLANTATION;

EID: 0036360906     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225100-00003     Document Type: Review

References (51)

1. A risk-benefit assessment of tacrolimus in transplantation
2. Consensus document: Therapeutic monitoring of tacrolimus (FK506)
3. Serious interaction between mibefadril and tacrolimus
4. Renal allograft dysfunction associated with rifampicin-tacrolimus interaction
5. Clinical management of tacrolimus drug interactions in renal transplant patients
6. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
7. Molecular pharmacology of immunosuppressive agents in relation to their clinical use
8. Tacrolimus: An update of its pharmacology and clinical efficacy in the management of organ transplantation
9. Pharmacokinetics, dosing principles, and blood level monitoring of FK506
10. Clinical pharmacokinetics of tacrolimus
11. Effect of low-and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects
12. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times post-transplant in renal transplant recipients
13. Comparative tacrolimus pharmacokinetics: Normal versus mildly hepatically impaired subjects
14. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients
15. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy
16. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506
17. Important interactions of drugs with immunosuppressive agents used in transplant recipients
18. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose
19. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxicholic acid in prevention of liver transplant rejection
20. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and p-glycoprotein
21. Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo
22. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promotor polymorphisms (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients
23. Plasma protein binding of tacrolimus in humans
24. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes
25. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506
26. Biological activity of tacrolimus (FK506) and its main metabolites from whole blood of kidney transplant recipients
27. In vitro metabolism of FK506, cytochrome P450 and drug interactions
28. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes
29. Effects of rifampicin on tacrolimus pharmacokinetics in healthy volunteers
30. Acute heart transplant rejection due to Saint John's wort
31. Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors
32. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels
33. Interaction between nelfinavir and tacrolimus after orthotopic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV)
34. Organ transplantation in the HIV-infected patient
35. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and p-glycoprotein
36. Drug-grapefruit juice interactions
37. Grapefruit juice and kinetics of tacrolimus
38. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation
39. Systemic antifungal agents: Drug interactions of clinical significance
40. Clinically significant drug interactions with new immunosuppressive drugs
41. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
42. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study
43. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
44. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
45. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression
46. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: Pharmacokinetics and tolerability
47. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
48. Tacrolimus/cerivastatin interaction study in liver transplant recipients
49. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients
50. Influence of hepatitis C virus infection on FK506 blood levels in renal transplant patients
51. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathioprine